跳转至内容
Merck
CN

HCCBP2MAG-58K

MILLIPLEX® Human Circulating Cancer Biomarker Magnetic Bead Panel 2 - Cancer Multiplex Assay

Circulating Cancer Biomarker Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple oncology biomarkers in various tumor types in human serum, plasma and cell culture samples.

登录 查看组织和合同定价。

关于此项目

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

MILLIPLEX® Human Circulating Cancer Biomarker Magnetic Bead Panel 2 - Cancer Multiplex Assay, Circulating Cancer Biomarker Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple oncology biomarkers in various tumor types in human serum, plasma and cell culture samples.

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 92-107%
standard curve range: 0.01-50 ng/mL
(Extracellular matrix protein 1)

standard curve range: 0.48-2,000 ng/mL
(All other biomarkers)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

Quality Level

Application

  • Analytes: Antithrombin III, Complement Factor H (CFH), Extracellular matrix Protein 1 (ECM1), Vitamin D binding protein
  • Recommended Sample Type: Human serum, plasma or tissue/cell culture supernatants or lysates
  • Note: Serum has a thrombin/antithrombin III complex bound to vitronectin. To accurately quantify antithrombin III concentrations we recommend using plasma samples because they lack the vitronectin/thrombin/antithrombin complex.
  • Recommended Sample Dilution: 25 μL of a 1:10,000 dilution of plasma or serum, or 25 μL of tissue/cell culture sample diluted in an appropriate control medium (dilution factors may vary)
  • Assay Run Time: Overnight (16-18 hours) at 2-8°C
  • Research Category: Cancer

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

General description

Circulating cancer biomarkers give insight beyond intracellular oncogenesis and into how the body responds to the presence of a tumor, the dysregulation of homeostasis, and the relationship between a tumor and its environment. Multianalyte panels have become essential tools that enable researchers to measure cancer biomarkers simultaneously, teasing out these relationships and applying them to understand tumor biology.

MILLIPLEX® Circulating Cancer Biomarker Panel 2 is a 4-plex kit that can be used for the simultaneous quantification of any or all of the following analytes in serum, plasma, tissue/cell lysate and culture supernatant samples: Extracellular matrix Protein 1 (ECM1), Antithrombin III, Vitamin D binding protein, and Complement Factor H (CFH). This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Circulating Cancer

Other Notes

Human Circulating Cancer Biomarker Panel 2 Standard (HCC-8058-2)

Human Circulating Cancer Biomarker Panel 2 Quality Controls 1 and 2 (HCC-6058-2)

Set of one 96-Well Plate with 2 Sealers

Bead Diluent (LBD-4)

Assay Buffer (L-AB)
Note: Contains 0.08% Sodium Azide

10X Wash Buffer (L-WB)
Note: Contains 0.05% Proclin

Human Circulating Cancer Biomarker Panel 2 Detection Antibodies (HCC-1058)

Streptavidin-Phycoerythrin (L-SAPE 6)
Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

法规信息

新产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ginette Tardif et al.
Arthritis research & therapy, 24(1), 120-120 (2022-05-24)
Osteoarthritis (OA) is a slowly developing and debilitating disease, and there are no validated specific biomarkers for its early detection. To improve therapeutic approaches, identification of specific molecules/biomarkers enabling early determination of this disease is needed. This study aimed at

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持